ARV-393 + Glofitamab
Phase 1Recruiting 0 watching 0 views this week๐ค Quiet
28
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Conditions
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Trial Timeline
Sep 5, 2024 โ Mar 1, 2028
NCT ID
NCT06393738About ARV-393 + Glofitamab
ARV-393 + Glofitamab is a phase 1 stage product being developed by Arvinas for Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06393738. Target conditions include Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL).
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06393738 | Phase 1 | Recruiting |
Competing Products
20 competing products in Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)